Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

PubWeight™: 4.67‹?› | Rank: Top 1%

🔗 View Article (PMID 28212060)

Published in N Engl J Med on February 17, 2017

Authors

Joaquim Bellmunt1, Ronald de Wit1, David J Vaughn1, Yves Fradet1, Jae-Lyun Lee1, Lawrence Fong1, Nicholas J Vogelzang1, Miguel A Climent1, Daniel P Petrylak1, Toni K Choueiri1, Andrea Necchi1, Winald Gerritsen1, Howard Gurney1, David I Quinn1, Stéphane Culine1, Cora N Sternberg1, Yabing Mai1, Christian H Poehlein1, Rodolfo F Perini1, Dean F Bajorin1, KEYNOTE-045 Investigators

Author Affiliations

1: From Dana-Farber Cancer Institute, Boston (J.B., T.K.C.); Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona (J.B.), and Fundación Instituto Valenciano de Oncología, Valencia (M.A.C.) - both in Spain; Erasmus MC Cancer Institute, Rotterdam (R.W.), and Radboud University Medical Center, Nijmegen (W.G.) - both in the Netherlands; Abramson Cancer Center, University of Pennsylvania, Philadelphia (D.J.V.); Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, QC, Canada (Y.F.); Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea (J.-L.L.); the University of California, San Francisco, San Francisco (L.F.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Smilow Cancer Hospital, Yale University, New Haven, CT (D.P.P.); Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (A.N.); Westmead Hospital and Macquarie University, Sydney (H.G.); the University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles (D.I.Q.); Hôpital Saint-Louis, Paris (S.C.); San Camillo and Forlanini Hospitals, Rome (C.N.S.); Merck, Kenilworth, NJ (Y.M., C.H.P., R.F.P.); and Memorial Sloan Kettering Cancer Center, New York (D.F.B.).

Associated clinical trials:

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | NCT02256436

Articles citing this

Pembrolizumab for Advanced Urothelial Carcinoma. N Engl J Med (2017) 1.40

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer (2017) 1.39

Immunotherapy: a new treatment paradigm in bladder cancer. Curr Opin Oncol (2017) 0.79

Bladder cancer: Pembrolizumab is superior to chemotherapy. Nat Rev Urol (2017) 0.75

Survival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Bladder Cancer (2017) 0.75

Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res (2017) 0.75

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. Onco Targets Ther (2017) 0.75

Urological cancer: Unravelling intertwined second-line options. Nat Rev Clin Oncol (2017) 0.75

Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. Breast Cancer (Auckl) (2017) 0.75

New treatment options for metastatic renal cell carcinoma. ESMO Open (2017) 0.75

PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. Oncotarget (2017) 0.75

Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. Ther Clin Risk Manag (2017) 0.75

A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol (2017) 0.75

Pembrolizumab for Advanced Urothelial Carcinoma. N Engl J Med (2017) 0.75

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer (2017) 0.75

Pembrolizumab for Advanced Urothelial Carcinoma. N Engl J Med (2017) 0.75

Cancer Immunotherapies: Are They as Effective in the Elderly? Drugs Aging (2017) 0.75

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. J Transl Med (2017) 0.75

PD-L1 blockade for urothelial carcinoma. Oncoimmunology (2017) 0.75

Articles cited by this

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71

Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (2016) 5.79

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2015) 5.42

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med (2016) 4.89

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64

Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol (2013) 1.58

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol (2016) 1.35

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol (2016) 1.12

The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget (2016) 0.94

Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol (2015) 0.93

The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. Oncotarget (2016) 0.92

Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol (2015) 0.90

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol (2017) 0.85

Molecular biology and targeted therapies for urothelial carcinoma. Cancer Treat Rev (2015) 0.83

Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther (2016) 0.83